Stimulants & ADHD Medications: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• LectureADHD

  Timothy E. Wilens

  An update on ADHD pharmacotherapy across the lifespan.

  ADHD

MasterPsych Psychiatry Conference 2026

October 19–22, 2026 · Newport Beach, CA

• LectureADHD: with Multiple Comorbidities and Special Populations

  Steven R. Pliszka

  Managing ADHD when it co-occurs with other disorders or arises in special populations.

  ADHD

• LectureADHD: Advanced Management Strategies

  Steven R. Pliszka

  Advanced medication strategies for ADHD beyond first-line stimulant trials.

  ADHD

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• LectureManaging Inattention in ADHD, Autism, and Intellectual Developmental Disorder

  Olivia Hindera

  Addresses managing inattention across ADHD, autism, and intellectual developmental disorder.

  ADHDAutism & Neurodevelopmental DisordersChild & Adolescent

• SymposiumStimulant Use Disorders in Youth and Young Adults: Innovations in Data, Identification, and Treatment

  Sara J. Polley · Gerald Busch · Niranjan S. Karnik · Laura A. Markley

  Covers new data, identification approaches, and treatment options for stimulant use disorders in adolescents and young adults.

  Child & AdolescentSubstance Use Disorders

• LectureUpdates in Stimulant Pharmacotherapy for ADHD: Recent Evidence and Clinical Considerations in Special Populations

  Raman Baweja

  Reviews recent evidence on stimulant treatment for ADHD and considerations for special populations.

  ADHDChild & Adolescent

• PosterSequential Pharmacotherapy for ADHD and Comorbid DMDD: Open-Label Lisdexamfetamine Followed by Randomized Adjunctive Fluoxetine vs Placebo

  Margaret Y. Yau · Sandra K. Loo · James J. McGough

  Reports a sequential trial of open-label lisdexamfetamine followed by randomized adjunctive fluoxetine versus placebo in youth with ADHD and disruptive mood dysregulation disorder.

  ADHDChild & Adolescent

• PosterMedication Experience and Adherence to Methylphenidate in Children With Fetal Alcohol Spectrum Disorder: A Qualitative Study

  Michel Spodenkiewicz

  Qualitative study of how children with fetal alcohol spectrum disorder experience and adhere to methylphenidate.

  ADHDAutism & Neurodevelopmental DisordersChild & Adolescent

See all 34 stimulants & adhd medications sessions at this meeting →

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• LectureCo-Managing ADHD and Bipolar Disorder: An Update in Pharmacologic Treatment

  Kristen Munyan · Natalie Jones-Brown

  Mood-first medication sequencing approach for comorbid ADHD and bipolar disorder to reduce destabilization risk. Pharmacology-eligible.

  ADHDBipolar Disorder

NEI Fall Congress 2026

November 5–8, 2026 · Colorado Springs, CO

• SymposiumResidual Symptoms in ADHD: From Circuitry to Clinical Strategy

  Jeffrey Robert Strawn · Andrew J. Cutler

  Links residual ADHD symptoms to underlying circuitry and offers strategies to optimize treatment response.

  ADHDNeuroscience & Mechanisms

• SymposiumTelehealth on Trial: Lessons From the Done.com Case for Safe and Ethical Prescribing

  David W. Goodman · Andrew J. Cutler

  Draws lessons from the Done.com telehealth prosecution for safe, ethical controlled-substance prescribing via telepsychiatry.

  Digital Psychiatry & AIPractice, Policy & Workforce

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• LectureE07 – Long-term effects of ADHD medication: new evidence from real-world data

  Guido Biele · Kenneth Man

  Real-world evidence on long-term academic outcomes and the safety of methylphenidate in children.

  ADHDChild & Adolescent

WCP 2026 — 26th World Congress of Psychiatry

September 23–26, 2026 · Stockholm, Sweden

• DebateDebate: ADHD - Adjunctive Stimulant for Depression Treatment – Pro-con?

  ADHDDepression

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• SymposiumFirst-Line Decisions: Lifestyle Modification or Medication? Balancing Pharmacologic and Non-Pharmacologic Care in ADHD

  James Greenblatt · Julie Carbray

  Guides initial ADHD treatment choices between stimulant/non-stimulant medication and behavioral, coaching, and environmental strategies based on severity, preference, and comorbidity.

  ADHDLifestyle & Integrative Psychiatry

• SymposiumMasterClass: Features Out of Focus: Recognition and Treatment of Emotional Dysregulation and Executive Dysfunction in ADHD

  Gregory Mattingly · Julie Carbray

  Highlights emotional dysregulation and executive dysfunction as underrecognized drivers of ADHD impairment, with neurobiological context and emerging pharmacologic options.

  ADHD

• SymposiumWomen, Hormones, and ADHD: What We Know, What We Don't, and What Clinicians Need to Understand

  Gregory Mattingly · Moushumi Mukerji

  Evidence-informed overview of how estrogen and progesterone shifts across the menstrual cycle, pregnancy, and perimenopause affect attention, mood, and stimulant response, with prescribing considerations amid research gaps.

  ADHDPerinatal & Women's Mental Health